A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia

References

• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry2004161341442514992963
   PubMed Web of Science ®Google Scholar
• LuftBTaylorDA review of atypical antipsychotic drugs versus conventional medication in schizophreniaExpert Opin Pharmacother20067131739174816925501
   PubMed Web of Science ®Google Scholar
• TandonRJibsonMDEfficacy of newer generation antipsychotics in the treatment of schizophreniaPsychoneuroendocrinology200328Suppl 192612504069
   PubMed Web of Science ®Google Scholar
• DoradoPBereczRPeñas-LledóEMLlerenaAAntipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphismExpert Opin Drug Metab Toxicol20073191917269891
   PubMed Web of Science ®Google Scholar
• HaddadPWeight change with atypical antipsychotics in the treatment of schizophreniaJ Psychopharmacol200519Suppl 6162716280334
   PubMedGoogle Scholar
• HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs2007211191193617927296
   PubMed Web of Science ®Google Scholar
• CacciaSPasinaLNobiliANew atypical antipsychotics for schizophrenia: iloperidoneDrug Des Devel Ther201043348
   PubMed Web of Science ®Google Scholar
• CacciaSPasinaLNobiliACritical appraisal of lurasidone in the management of schizophreniaNeuropsychiatr Dis Treat2012815516822570547
   PubMed Web of Science ®Google Scholar
• ChuePChueJA review of paliperidone palmitateExpert Rev Neurother201212121383139723237346
   PubMed Web of Science ®Google Scholar
• CitromeLAsenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychoticInt J Clin Pract200963121762178419840150
   PubMed Web of Science ®Google Scholar
• KishiTMatsudaYNakamuraHIwataNBlonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trialsJ Psychiatr Res201347214915423131856
   PubMed Web of Science ®Google Scholar
• CitromeLCariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerabilityExpert Opin Drug Metab Toxicol20139219320623320989
   PubMed Web of Science ®Google Scholar
• GrunderGCariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depressionCurr Opin Investig Drugs2010117823832
   PubMed Web of Science ®Google Scholar
• Agai-CsongorEDományGNógrádiKDiscovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptorsBioorg Med Chem Lett201222103437344022537450
   PubMed Web of Science ®Google Scholar
• KissBHorváthANémethyZCariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profileJ Pharmacol Exp Ther2010333132834020093397
   PubMed Web of Science ®Google Scholar
• JoyceJNMillanMJDopamine D3 receptor antagonists as therapeutic agentsDrug Discov Today2005101391792515993811
   PubMed Web of Science ®Google Scholar
• TadoriYForbesRAMcQuadeRDKikuchiTIn vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptorsEur J Pharmacol2011668335536521816144
   PubMed Web of Science ®Google Scholar
• KissBHortiFBobokACariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychoticsBiol Psychiatry2012718 Suppl 140S
   Web of Science ®Google Scholar
• ArranzMJde LeonJPharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of researchMol Psychiatry200712870774717549063
   PubMed Web of Science ®Google Scholar
• Newman-TancrediAKlevenMSComparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor propertiesPsychopharmacology (Berl)2011216445147321394633
   PubMed Web of Science ®Google Scholar
• KissBPetersonSNemethyZFazekasKMasriBCaronMEffects of cariprazine on D2 and D3 dopamine receptor signalling mechanisms in vitroBasic and Clin Pharmacol Toxicol2010107Suppl 1379
   Google Scholar
• ChiodoLABunneyBSTypical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neuronsJ Neurosci198338160716196135762
   PubMed Web of Science ®Google Scholar
• WhiteFJWangRYDifferential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neuronsScience19832214615105410576136093
   PubMed Web of Science ®Google Scholar
• Adham-ParangiNKissBGyertyanIRGH-188, a potential antipsychotic with D3/D2 antagonist/partial agonist properties, exhibits an atypical antipsychotic profile in rats with respect to effect on spontaneously active dopamine neuronsInt J Neuropsychopharmacol200811Suppl 1P-07.69 http://dx.doi.org/10.1017/S1461145708009462
   Google Scholar
• TaraziFChoiYKAdhamNKissBGyertyánIEffects of chronic exposure of cariprazine on dopamine receptor subtypesEur Neuropsychopharmacol201222Suppl 2S349S350
   Web of Science ®Google Scholar
• TaraziFChoiYKAdhamNKissBGyertyánIEffects of chronic cariprazine administration on serotonin and glutamate receptor subtypesNeurpsychopharmacology201238Suppl 1S167
   PubMedGoogle Scholar
• GyertyánIKissBSaghyKBehavioral profile of RGH-188, a novel dopamine D3/D2 antagonist/partial agonist in rodentsPresented at: 36th Annual Meeting of the Society for NeuroscienceOctober 13–17, 2006Atlanta, GA
   Google Scholar
• YasumatsuHShiigiYHallsBHEffects of RGH-188, a novel dopamine D3/D2 antagonist/partial agonist, on apomorphine-induced prepulse inhibition deficits and g-butyrolactone-induced increases in dopamine synthesis ratePresented at: 37th Annual Meeting of the Society for NeuroscienceNovember 12–16, 2007San Diego, CA
   Google Scholar
• AdhamNGyertyánIKissBCariprazine shows dopamine D3 receptor-dependent procognitive effects on working memory and social recognition and interactionBiol Psychiatry2011699 Suppl 1188S
   PubMed Web of Science ®Google Scholar
• AdhamNGyertyánIKissBCariprazine attenuates PCP-induced increases in prefrontal cortical glutamate levels and deficits in cognition and social behaviourEur Neuropsychopharmacol201222Suppl 2S347http://embase.com/search/results?subaction=viewrecord&rid=5&page=1&L70909566
   PubMed Web of Science ®Google Scholar
• CarliMCalcagnoEMainolfPMaininiEInvernizziRWEffects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortexPsychopharmacology (Berl)2011214363965221052982
   PubMed Web of Science ®Google Scholar
• CarliMCalcagnoEMaininiEArntJInvernizziRWSertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPPPsychopharmacology (Berl)2011214362563721049266
   PubMed Web of Science ®Google Scholar
• DumanRDuricVBanasrMAdhamNKissBGyertyánICariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedoniaNeuropsychopharmacology201238Suppl 1S84S85
   Google Scholar
• AdhamNGyertyanIKissBCariprazine, a D3-preferring dopamine D3/D2 receptor partial agonist, has antidepressant-like activity with fast onset of action in the chronic mild stress-induced anhedonia modelNeuropsychopharmacology201035Suppl 1S171
   Google Scholar
• PetersonSMasriBGaoBInterference with D2 dopamine receptor b-arrestin 2 signaling may relate to the antimanic effects of cariprazineBiol Psychiatry2010679 Suppl 1234S235S
   Web of Science ®Google Scholar
• SenecaNFinnemaSJLaszlovszkyIOccupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomographyPsychopharmacology (Berl)2011218357958721625907
   PubMed Web of Science ®Google Scholar
• CacciaSPharmacokinetics and metabolism update for some recent antipsychoticsExpert Opin Drug Metab Toxicol20117782984621476873
   PubMed Web of Science ®Google Scholar
• KirschnerNGemesiLIVastagMIn vitro metabolism of RGH-188Drug Metab Rev200840Suppl 1128129
   Google Scholar
• MeszarosG PKapasMBorsosMPharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjectsEur Neuropsychopharmacol2007217Suppl 4S451S452
   Google Scholar
• MeszarosG PAgai-CsongorEKapasMSensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urineJ Pharm Biomed Anal200848238839718242914
   PubMed Web of Science ®Google Scholar
• TóthMVarroneASteigerCBrain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primatesSynapse201367525826423238770
   PubMed Web of Science ®Google Scholar
• MoonsTde RooMClaesSDomGRelationship between P-glycoprotein and second-generation antipsychoticsPharmacogenomics20111281193121121843066
   PubMed Web of Science ®Google Scholar
• CitromeLCariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapyAdv Ther201330211412623361833
   PubMed Web of Science ®Google Scholar
• CitromeLCariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapyAdv Ther201330210211323361832
   PubMed Web of Science ®Google Scholar
• BoseAStaraceAWangQCariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, Phase III trialEur Neuropsychopharmacol201222Suppl 2S285
   Web of Science ®Google Scholar
• KnesevichMPapadakisKBoseAThe efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a Phase II trialEur Neuropsychopharmacol200919Suppl 3S469S470
   Web of Science ®Google Scholar
• LaszlovszkyIBoseAAndorGThe efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a Phase II trialInt Clin Psychopharmacol201126Suppl Ae15
   Google Scholar
• ZukinSRKaneJCutlerAEfficacy and safety of cariprazine in acute exacerbation of schizophrenia: a Phase III, international, randomized double-blind, placebo-controlled trialNeuropsychopharmacology201238Suppl 1S319
   Google Scholar
• National Institute for Health and Care ExcellenceNew drug application submitted to FDA for cariprazine for treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder Available from: https://www.evidence.nhs.uk/document?ci=http%3A%2F%2Fwww.businesswire.com%2Fportal%2Fsite%2Fbiospace%2Ftemplate.PAGE%2Fmenuitem.ab520ce17e34ab71ff00d635c0908a0c%2Findex.jsp%3FndmViewId%3Dnews_view%26newsId%3D20121127006648%26newsLang%3Den%3Ffromsource%3Dnelm&q=cariprazine&ReturnUrl=%2Fsearch%3Fq%3DcariprazineAccessed July 23, 2013
   Google Scholar
• Forest LaboratoriesForest Laboratories, Inc, and Gedeon Richter Plc. announce results from two positive Phase III trials with the investigational antipsychotic cariprazine for the treatment of schizophrenia [press release]New YorkForest Laboratories2012 [February 28]. Available from: http://news.frx.com/press-release/rd-news/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-two-positive-pAccessed July 9, 2013
   Google Scholar
• SicardMNZaiCCTiwariAKPolymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysisPharmacogenomics201011111561157121121776
   PubMed Web of Science ®Google Scholar
• RothmanRBBaumannMHSavageJEEvidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medicationsCirculation2000102232836284111104741
   PubMed Web of Science ®Google Scholar
• BuchholzSMorrowA FColemanPLAtypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanismsIntern Med J200838760260618715305
   PubMed Web of Science ®Google Scholar
• NewcomerJ WMetabolic considerations in the use of antipsychotic medications: a review of recent evidenceJ Clin Psychiatry200768Suppl 1202717286524
   PubMed Web of Science ®Google Scholar